The FDA has been cracking down on companies and clinics that market unapproved, unproven stem cell therapies, but some of the organizations' trials remain listed on clinicaltrials.gov, which critics say gives the firms undeserved credibility. Critics also say that charging participants, as some stem cell studies do, is unethical, and trials run by unapproved sellers threaten participation in valid studies that comply with federal regulations.
Potentially dodgy stem cell trials threaten valid studies
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.